Expert: Fully human monoclonal antibody targeting coagulation Factor XI (FXI). Inhibits the intrinsic/contact pathway of coagulation (thrombus propagation) while preserving the extrinsic/tissue factor pathway (hemostasis). Decouples antithrombotic efficacy from bleeding risk.

Everyday: Blocks Factor XI in the blood clotting cascade — a step involved in forming dangerous blood clots but NOT in stopping bleeding from wounds. This separation means you can prevent clots with potentially much less bleeding risk than traditional blood thinners.

Targets: ["Factor XI","FXI"]

Anti-Factor XI antibody for VTE prevention. Targets the intrinsic coagulation pathway to prevent clots while potentially preserving hemostasis (less bleeding than DOACs/warfarin). Competes with abelacimab (Anthos/AZN), milvexian (BMS oral FXIa), asundexian (Bayer oral FXIa). SC dosing (monthly or less frequent). Major unmet need: all current anticoagulants carry significant bleeding risk.